NightHawk Biosciences (NYSE:NHWK – Get Rating) – Stock analysts at Cantor Fitzgerald boosted their FY2022 EPS estimates for NightHawk Biosciences in a research note issued on Wednesday, May 18th. Cantor Fitzgerald analyst K. Kluska now anticipates that the biopharmaceutical company will post earnings per share of ($1.29) for the year, up from their previous forecast of ($2.10). Cantor Fitzgerald currently has a “Overweight” rating on the stock.
Several other research firms have also recently weighed in on NHWK. B. Riley cut their price objective on NightHawk Biosciences from $10.00 to $8.00 and set a “buy” rating for the company in a research report on Friday, March 18th. StockNews.com initiated coverage on NightHawk Biosciences in a report on Thursday, March 31st. They set a “sell” rating for the company. One analyst has rated the stock with a sell rating and four have given a buy rating to the company. According to MarketBeat.com, NightHawk Biosciences currently has a consensus rating of “Buy” and an average price target of $14.33.
NightHawk Biosciences (NYSE:NHWK – Get Rating) last announced its quarterly earnings results on Monday, May 16th. The biopharmaceutical company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.09. NightHawk Biosciences had a negative return on equity of 30.28% and a negative net margin of 1,995.52%.
Institutional investors have recently modified their holdings of the stock. Wolverine Trading LLC bought a new stake in shares of NightHawk Biosciences in the fourth quarter worth $33,000. Walleye Trading LLC acquired a new position in NightHawk Biosciences in the fourth quarter valued at $55,000. Walleye Capital LLC acquired a new position in NightHawk Biosciences in the fourth quarter valued at $76,000. Cubist Systematic Strategies LLC acquired a new position in NightHawk Biosciences in the fourth quarter valued at $82,000. Finally, Goldman Sachs Group Inc. lifted its holdings in NightHawk Biosciences by 12.5% in the fourth quarter. Goldman Sachs Group Inc. now owns 56,465 shares of the biopharmaceutical company’s stock valued at $171,000 after buying an additional 6,278 shares during the period. 18.12% of the stock is currently owned by institutional investors.
About NightHawk Biosciences (Get Rating)
Heat Biologics, Inc, an integrated biopharmaceutical company, engages in the development of immune therapies and vaccines. The company's therapies are used to modulate the immune system against various diseases, including cancer and infectious diseases. Its gp96 platform, including ImPACT, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and ComPACT, which delivers antigen driven T-cell activation and specific co-stimulation in a single product.
- Get a free copy of the StockNews.com research report on NightHawk Biosciences (NHWK)
- MarketBeat: Week in Review 5/16 – 5/20
- 3 Retailers That Defied First Quarter Headwinds
- Will John Deere’s Earnings Help to Calm the Markets?
- Rapid7: Could Be Profitable in FY 2022 Despite Bear Market
- Lowe’s Companies Has Not Bottomed
Receive News & Ratings for NightHawk Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NightHawk Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.